
|Articles|October 1, 2012
Agent delays bone metastases in men with castration-resistant prostate cancer
The RANK ligand inhibitor denosumab (XGEVA) may be able to prevent or at least delay multiple and/or symptomatic bone metastases in men with castration-resistant prostate cancer (CRPC) at high risk of bone metastases.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study launches of MRI plus PSMA-PET imaging for prostate cancer detection
2
CREST and POTOMAC: Redefining immunotherapy’s role in NMIBC
3
Practical uses of AI across the urologic care continuum
4
How to manage bladder symptoms that fluctuate with your cycle
5



















